The invention relates to the diagnosis of stroke resulting from occlusion of one or more large vessels in the brain, and in particular to the diagnosis of stroke resulting from occlusion of one or more large vessels in the brain using one or more biomarkers.

A method for treating vasospasm may include measuring cerebrospinal fluid (CSF) to obtain a baseline biomarker value. The method may include administering a first dose of a trehalose solution. The method may include draining the CSF to maintain a current intracranial pressure (ICP). The method may include measuring a trehalose concentration in the CSF. The method may include measuring a biomarker value in the CSF. The method may end based on a determination that the measured biomarker value indicates a predetermined biomarker concentration.

The present disclosure pertains to predicting an onset of a cerebral hemorrhagic event in a subject by testing a blood sample of the subject for the presence or absence of one or more indicators; and correlating the presence or absence of the one or more indicators to the subjects risk for suffering from the cerebral hemorrhagic event, where the presence of the one or more indicators is correlated to an increased risk in the subject for suffering from the cerebral hemorrhagic event and where the absence of the one or more indicators is correlated to a decreased risk in the subject for suffering from the cerebral hemorrhagic event. The methods of the present disclosure may also include implementing a therapeutic decision in order to prevent the cerebral hemorrhagic event. The present disclosure also pertains to kits for use in predicting an onset of a cerebral hemorrhagic event in a subject.

The present invention relates to methods of detecting a neural injury biomarker in a biological sample. The method includes subjecting a biological sample to an assay according to the present invention that produces a measurable signal and detecting the measurable signal. The presence or absence of the measurable signal indicates the presence or absence of the biomarker in the sample. The present invention also relates to methods of determining the state of a subject's neural injury. The present invention also relates to systems and devices useful in carrying out the methods of the present invention.

Provided is a lateral flow assay device capable of detecting a traumatic brain injury marker including a sample pad into which a blood sample containing a traumatic brain injury marker is injected, an adsorption pad including a probe which is mixed to the marker when the traumatic brain injury marker moves from the sample pad to form a traumatic brain injury marker complex, and a porous film which fluid-communicates with the adsorption pad and capillary-migrates the traumatic brain injury marker complex from the adsorption pad to a detection line, in which the probe includes a capture antibody consisting of an antibody labeled with a specific binding material specifically binding to the traumatic brain injury marker and a detector antibody consisting of an antibody labeled with a fluorescent material having a relatively long emission lifetime of 1 microsecond or more, and a mixture of at least two different kinds-origin antibodies is used as the antibody labeled with the specific binding material or the fluorescent material.

Disclosed herein are methods that aid in the determination of whether a subject has a traumatic brain injury (TBI) by detecting levels of at least one biomarker, glial fibrillary acidic protein (GFAP), in samples taken from a subject, such as a human subject, where the subject has received a head CT scan that is negative for a TBI.

The invention relates to methods of cardiovascular imaging and/or measurement of blood markers for detecting, diagnosing and/or prognosing cardiac or myocardial microbleeds, especially in subject with hypertension and cardiovascular diseases. Treatment methods are also provided for subjects identified, diagnosed, prognosed, or detected with cardiac or myocardial microbleeds. In some embodiments, the subject has hypertension-induced microbleeds, but has not had a myocardial infarction or reperfusion therapy.

Provided are compositions and methods for differentiating and diagnosing ischemic stroke and subgroups thereof (e.g., cardioembolic stroke, large vessel stroke, atherothrombotic stroke, lacunar stroke) from intracerebral hemorrhage.

A method of diagnosing central nervous system injuries such as acquired brain injury (ABI) and/or acquired spinal cord injury (ASI), including mild TBI (concussion or blast wave), mild ASI (contusion, stretch or partial cord transection), non-TBI brain injury and/or non-TSI spinal cord injury in a subject (animal or human). The method includes (a) obtaining a biological test sample from the subject, identifying metabolites in the subject's sample using metabolomics thereby obtaining a subject's metabolite matrix and generating a subject's profile using the patient's metabolite matrix; and (b) using multivariate statistical analysis and machine learning to compare the subject's profile with predetermined set of profiles of CNS injuries and a predetermined set of profiles of controls to determine if the subject has a CNS injury.

The invention relates to a method for selecting a patient suffering stroke for a reperfusion therapy based on determining the level of retinol binding protein-4 (RBP4) and N-terminal fragment of B-type natriuretic peptide (NT-proBNP) in an isolated sample of said patient. The invention also relates to a method of differentiating ischemic stroke from haemorrhagic stroke and to kits comprising reagents to carry out the methods.